D De Neubourg1, K Bogaerts2, C Blockeel3, T Coetsier4, A Delvigne5, F Devreker6, M Dubois7, N Gillain8, S Gordts9, C Wyns10. 1. Leuven University Fertility Centre, University Hospitals Leuven, 3000 Leuven, Belgium diane.deneubourg@telenet.be. 2. I-BioStat, KU Leuven, 3000 Leuven and Universiteit Hasselt, 3500 Hasselt, Belgium. 3. Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, 1090 Brussels, Belgium. 4. Fertility Centre, AZ St Lucas, 9000 Ghent, Belgium. 5. Centre de Procréation Médicalement Assistée, Clinique Saint-Vincent, 4000 Liège, Belgium. 6. Laboratoire de Procréation Médicalement Assistée, Université Libre de Bruxelles, Hôpital Erasme, 1070 Brussels, Belgium. 7. Centre de Procréation Médicalement Assistée, Université de Liège, 4000 Liège, Belgium. 8. Nutrition, Environment and Health, University of Liège, 4000 Liège, Belgium. 9. Leuven Institute for Fertility and Embryology, 3000 Leuven, Belgium. 10. Department of Gynaecology-Andrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium.
Abstract
STUDY QUESTION: How do the national cumulative (multiple) live birth rates over complete assisted reproduction technology (ART) courses of treatment per woman in Belgium compare to those in other registries? SUMMARY ANSWER: Cumulative live birth rates (CLBRs) remain high with a low cumulative multiple live birth rate when compared with other registries and publications. WHAT IS KNOWN ALREADY: In ART, a reduction in the multiple live birth rate could be achieved by reducing the number of embryos transferred. It has been shown that by doing so, live birth rates per cycle were maintained, particularly when the augmentation effect of attached frozen-thawed cycles was considered. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study included all patients with a Belgian national insurance number who were registered in the national ART registry (Belrap) and who started a first fresh ART cycle between 1 July 2009 until 31 December 2011 with follow up until 31 December 2012. We analysed 12 869 patients and 38 008 cycles (both fresh and attached frozen cycles). PARTICIPANTS, MATERIALS, SETTINGS, METHODS: CLBRs per patient who started a first ART cycle including fresh and consecutive frozen cycles leading to a live birth. Conservative estimates of cumulative live birth assumed that patients who did not return for treatment had no chance of achieving an ART-related live birth, whereas optimal estimates assumed that women discontinuing treatment would have the same chance of achieving a live birth as those continuing treatment. A maximum of six fresh ART cycles with corresponding frozen cycles was investigated and compared with other registries and publications. MAIN RESULTS AND ROLE OF CHANCE: The CLBR was age dependent and declined from 62.9% for women <35 years, to 51.4% for women 35-37 years, to 34.1% for women 38-40 years and 17.7% for women 41-42 years in the conservative analysis after six cycles. In the optimal estimate, the CLBR declined from 85.9% for women <35 years, to 72.0% for women 35-37 years, to 50.4% for women 38-40 years and 36.4% for women 41-42 years. The cumulative multiple live birth rates for the whole population were 5.1 and 8.6% for the conservative and optimal estimate, respectively. LIMITATIONS, REASONS FOR CAUTION: Conservative and optimal estimates use assumptions for the whole ART population and do not take the individual patient into account. WIDER IMPLICATIONS OF THE FINDINGS: These data reinforce the validity of the Belgian model of coupling reimbursement of ART costs to a restriction in the number of embryos transferred. Our data can improve decision-making in medical ART practice both on the patient level and for society at large and could provide health care takers and insurance companies with a valid model. STUDY FUNDING COMPETING INTERESTS: none.
STUDY QUESTION: How do the national cumulative (multiple) live birth rates over complete assisted reproduction technology (ART) courses of treatment per woman in Belgium compare to those in other registries? SUMMARY ANSWER: Cumulative live birth rates (CLBRs) remain high with a low cumulative multiple live birth rate when compared with other registries and publications. WHAT IS KNOWN ALREADY: In ART, a reduction in the multiple live birth rate could be achieved by reducing the number of embryos transferred. It has been shown that by doing so, live birth rates per cycle were maintained, particularly when the augmentation effect of attached frozen-thawed cycles was considered. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study included all patients with a Belgian national insurance number who were registered in the national ART registry (Belrap) and who started a first fresh ART cycle between 1 July 2009 until 31 December 2011 with follow up until 31 December 2012. We analysed 12 869 patients and 38 008 cycles (both fresh and attached frozen cycles). PARTICIPANTS, MATERIALS, SETTINGS, METHODS:CLBRs per patient who started a first ART cycle including fresh and consecutive frozen cycles leading to a live birth. Conservative estimates of cumulative live birth assumed that patients who did not return for treatment had no chance of achieving an ART-related live birth, whereas optimal estimates assumed that women discontinuing treatment would have the same chance of achieving a live birth as those continuing treatment. A maximum of six fresh ART cycles with corresponding frozen cycles was investigated and compared with other registries and publications. MAIN RESULTS AND ROLE OF CHANCE: The CLBR was age dependent and declined from 62.9% for women <35 years, to 51.4% for women 35-37 years, to 34.1% for women 38-40 years and 17.7% for women 41-42 years in the conservative analysis after six cycles. In the optimal estimate, the CLBR declined from 85.9% for women <35 years, to 72.0% for women 35-37 years, to 50.4% for women 38-40 years and 36.4% for women 41-42 years. The cumulative multiple live birth rates for the whole population were 5.1 and 8.6% for the conservative and optimal estimate, respectively. LIMITATIONS, REASONS FOR CAUTION: Conservative and optimal estimates use assumptions for the whole ART population and do not take the individual patient into account. WIDER IMPLICATIONS OF THE FINDINGS: These data reinforce the validity of the Belgian model of coupling reimbursement of ART costs to a restriction in the number of embryos transferred. Our data can improve decision-making in medical ART practice both on the patient level and for society at large and could provide health care takers and insurance companies with a valid model. STUDY FUNDING COMPETING INTERESTS: none.
Authors: C Wyns; C De Geyter; C Calhaz-Jorge; M S Kupka; T Motrenko; J Smeenk; C Bergh; A Tandler-Schneider; I A Rugescu; V Goossens Journal: Hum Reprod Open Date: 2022-07-05
Authors: Lucy Prentice; Lynn Sadler; Sarah Lensen; Melissa Vercoe; Jack Wilkinson; Richard Edlin; Georgina M Chambers; Cynthia M Farquhar Journal: Hum Reprod Open Date: 2020-09-22
Authors: Ghadeer L Aljahdali; Fatimah A Alkhaldi; Sarah F Almujarri; Haifa F Alsadhan; Amirah S Yaqoub; Jawaher A Alsahabi; Nazish Masud; Afaf A Felemban Journal: Cureus Date: 2021-05-06
Authors: C Wyns; Ch De Geyter; C Calhaz-Jorge; M S Kupka; T Motrenko; J Smeenk; C Bergh; A Tandler-Schneider; I A Rugescu; S Vidakovic; V Goossens Journal: Hum Reprod Open Date: 2021-08-05
Authors: Tessy Boedt; Eline Dancet; Sharon Lie Fong; Karen Peeraer; Diane De Neubourg; Sofie Pelckmans; Arne van de Vijver; Jan Seghers; Katleen Van der Gucht; Ben Van Calster; Carl Spiessens; Christophe Matthys Journal: BMJ Open Date: 2019-07-30 Impact factor: 2.692
Authors: Inge Van Vaerenbergh; Tom Adriaenssens; Wim Coucke; Lisbet Van Landuyt; Greta Verheyen; Michaël De Brucker; Michel Camus; Peter Platteau; Michel De Vos; Elien Van Hecke; André Rosenthal; Johan Smitz Journal: Reprod Biol Endocrinol Date: 2021-02-19 Impact factor: 5.211
Authors: Ch De Geyter; C Wyns; C Calhaz-Jorge; J de Mouzon; A P Ferraretti; M Kupka; A Nyboe Andersen; K G Nygren; V Goossens Journal: Hum Reprod Date: 2020-12-01 Impact factor: 6.918